A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
Study Identifier:
382-201-00034
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Anxiety
Study Drug
- Drug: SEP-363856
Date
Oct 2026 - May 2029
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
- Key Inclusion Criteria
- Male or female participants at least 18 years of age at the time of informed consent
- Completed one of the prior GAD Phase 3 studies involving SEP-363856 through Week 8 without discontinuation of trial intervention
- Able to continue treatment without interruption, and is considered by investigator to potentially benefit from SEP-363856
- Participant is willing and able to comply with study procedures and visit schedule
- i) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
- Key Exclusion Criteria
- Diagnosis other than GAD that is the primary focus of treatment
- Clinically significant psychiatric or medical condition that may interfere with study participation
- Lifetime history of meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for, or was diagnosed during the prior study with, a psychiatric disorder that would compromise accurate assessment of safety and efficacy outcomes
- Clinically significant abnormal laboratory values or ECG findings
- Significant suicide risk
- Substance use/positive drug screen
- Use of prohibited medications/therapies
- Known sensitivity to SEP-363856
Protocol Summary
This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult participants with generalized anxiety disorder (GAD) over a treatment period of 26 weeks.
Study Locations
Location
Status
Location
Clinical Neuroscience Solutions, LLC
Jacksonville, Florida, United States, 32256
Status
Recruiting
Location
Clinical Neuroscience Solutions Inc. (CNS) - Orlando
Orlando, Florida, United States, 32801
Status
Recruiting
Location
Basil Clinical
Jamaica, New York, United States, 11413
Status
Recruiting
Location
Manhattan Behavioral Medicine PLLC
New York, New York, United States, 10036
Status
Recruiting
© 2025 Otsuka America Pharmaceutical,
Inc All rights reserved.
July 2025 01US25EUC0279
Requirements information
- Key Inclusion Criteria
- Male or female participants at least 18 years of age at the time of informed consent
- Completed one of the prior GAD Phase 3 studies involving SEP-363856 through Week 8 without discontinuation of trial intervention
- Able to continue treatment without interruption, and is considered by investigator to potentially benefit from SEP-363856
- Participant is willing and able to comply with study procedures and visit schedule
- i) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
- Key Exclusion Criteria
- Diagnosis other than GAD that is the primary focus of treatment
- Clinically significant psychiatric or medical condition that may interfere with study participation
- Lifetime history of meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for, or was diagnosed during the prior study with, a psychiatric disorder that would compromise accurate assessment of safety and efficacy outcomes
- Clinically significant abnormal laboratory values or ECG findings
- Significant suicide risk
- Substance use/positive drug screen
- Use of prohibited medications/therapies
- Known sensitivity to SEP-363856